CTXR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Citius Pharmaceuticals Inc (CTXR) is not a strong buy at the moment for a beginner investor with a long-term strategy. The financial performance is weak, technical indicators are mixed, and there are no significant positive catalysts or trading signals to support a buy decision. It is better to hold off for now and monitor the stock for better entry points or improved fundamentals.
The MACD is positive and expanding, indicating a slight bullish momentum. However, the RSI is neutral at 53.359, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key resistance levels, with support at 0.663 and resistance at 0.776. Overall, the technical indicators do not strongly support a buy decision.
NULL identified. There is no recent news, no significant hedge fund or insider trading activity, and no recent congress trading data.
Weak financial performance with declining net income (-15.84% YoY) and EPS (-70.77% YoY). The stock also lacks strong trading signals or positive sentiment from technical or options data.
In Q1 2026, revenue remained flat YoY at $3,944,111. Net income dropped to -$8,220,785 (-15.84% YoY), and EPS declined significantly to -0.38 (-70.77% YoY). Gross margin remained stable at 79.99%. Overall, financial performance is weak, with no signs of growth.
No data available for trend analysis or analyst ratings. Wall Street sentiment is unclear.
